Krystal Biotech (KRYS) Receivables (2023 - 2026)

Krystal Biotech has disclosed Receivables across 4 years of filings, most recently posting $127.0 million for Q1 2026.

• Receivables for Q1 2026 came in at $127.0 million, up 22.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.0 million (up 22.94% YoY), and the FY2025 annual result was $127.4 million, up 21.63% from the prior year.
• Receivables came in at $127.0 million for Q1 2026 at Krystal Biotech, roughly flat from $127.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $129.6 million in Q3 2025 to a low of $9.3 million in Q3 2023.
• The 4-year median for Receivables is $104.7 million (2024), against an average of $96.4 million.
• Across the five-year window, Receivables soared 946.22% in 2024 and fell 1.38% in 2025, its largest moves.
• Krystal Biotech's Receivables stood at $42.0 million in 2023, then jumped by 149.16% to $104.7 million in 2024, then gained by 21.63% to $127.4 million in 2025, then declined by 0.31% to $127.0 million in 2026.
• The last three Receivables figures came in at $127.0 million (Q1 2026), $127.4 million (Q4 2025), and $129.6 million (Q3 2025), per Business Quant data.